About: Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
Creator	Zhang, Li Li, Xiaoyu Wang, Meng Huang, Weijin Nie, Jianhui Wang, Youchun Lu, Qiong Fan, Changfa Li, Qianqian Liu, Huan Xu, Miao Hao, Huan Liu, Junkai Nie, Lingling Qin, Haiyang Sun, Qiyu Wu, Jiajing Zhao, Chenyan
Source	Medline; PMC
abstract	Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.
has issue date	2020-03-24(xsd:dateTime)
bibo:doi	10.1080/22221751.2020.1743767
bibo:pmid	32207377
has license	cc-by
sha1sum (hex)	34aa3019092aa11deeae183727cc28c5a92ead73
schema:url	https://doi.org/10.1080/22221751.2020.1743767
resource representing a document's title	Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
has PubMed Central identifier	PMC7144318
has PubMed identifier	32207377
schema:publication	Emerg Microbes Infect
resource representing a document's body	covid:34aa3019092aa11deeae183727cc28c5a92ead73#body_text
is schema:about of	named entity 'mouse' named entity 'patient' named entity 'inoculum' named entity 'Establishment' named entity 'numbers' named entity 'When' named entity 'human' named entity 'level' named entity 'developers' named entity 'neutralization' named entity 'sera' named entity 'VSV' named entity 'convalescent' named entity 'production system' named entity 'robust' named entity 'SARS-CoV-2' named entity 'glad' named entity 'virus' named entity 'SARS-CoV-2' named entity 'facilities' named entity 'neutralization' named entity 'Pseudoviruses' named entity 'serum samples' named entity 'cutoff values' named entity 'emerging viruses' named entity 'pathogenicity' named entity 'vaccines' named entity 'cell lines' named entity 'recombinant' named entity 'pseudovirus' named entity 'infection' named entity 'serum samples' named entity 'inocula' named entity 'Monomer' named entity 'virus' named entity 'virus' named entity 'genome' named entity 'SARS-CoV' named entity 'virus' named entity 'coronaviruses' named entity 'cell lines' named entity 'PerkinElmer' named entity 'protein' named entity 'pseudovirus' named entity 'GraphPad Prism' named entity 'lysate' named entity 'vaccines' named entity 'pseudovirus' named entity 'PBS' named entity 'MDCK' named entity 'respiratory diseases' named entity 'SARS-CoV-2' named entity 'Lassa virus' named entity 'coronavirus disease 2019' named entity 'protein' named entity 'LOD' named entity 'SARS-CoV-2' named entity 'antibody' named entity 'pseudovirus' named entity 'incubation' named entity 'kidney' named entity 'infection' named entity 'virus' named entity 'pseudovirus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software